A Phase 1, First-in-human Study of VX-668
Learn more about:
Related Clinical Trial
A Phase 1, First-in-human Study of VX-668
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
A Phase 1, First-in-human Study of VX-634
A Phase I of OsrhAAT in Healthy Volunteers
Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease
A Study of Belcesiran in Patients With A1ATD-Associated Liver Disease
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
A Single Ascending and Repeated Dose Study of Oral ZF874 in Healthy Volunteers and PiMZ Subjects
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
COPD Exacerbation Blood and Urine Biomarkers Study
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
Alpha-1 Carrier Genomics Study
Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
Study of ARO-AAT in Normal Adult Volunteers
Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home
AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
Environment Effect on Six-Minute Walk Test Performance
Alpha-1 Foundation DNA and Tissue Bank
Alpha1-antitrypsin Deficiency Registry
Alpha-1 Research Registry
Long-Term Follow-up Study of ADVM-043
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Alpha-1 Coded Testing(ACT) Study
4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?
Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin Deficiency
Management of Patients With Alpha-1 Antitrypsin Deficiency Associated Emphysema
Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation”
EARCO REGISTRY. History Of Patients With Alpha-1 Antitrypsin
GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency
Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency
Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Subjects With Alpha 1-Antitrypsin Deficiency
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency
Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency
Alpha-1 Foundation Research Registry
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients
Evaluate Efficacy and Safety of “Kamada-AAT for Inhalation” in Patients With AATD
A Study of DCR-A1AT in Healthy Adult Volunteers and Patients With A1ATD-Associated Liver Disease
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
Effects of Different Exercise Training Modalities in Alpha-1 Antitrypsin Deficiency Patients
Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficiency
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)
Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 – Proteinase Inhibitor)
Aralast alpha1-proteinase Inhibitor Surveillance Study
The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency
The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency